Ocher Rebecca, May Megan, Labin Jonathan, Shah Janki, Horwich Tamara, Watson Karol E, Yang Eric H, Calfon Press Marcella A
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
Division of Cardiology, Department of Medicine, MedStar Health, Washington, DC.
J Soc Cardiovasc Angiogr Interv. 2023 May 16;2(4):101032. doi: 10.1016/j.jscai.2023.101032. eCollection 2023 Jul-Aug.
Mitral regurgitation is the most common valvular disease, particularly in older adults. Recent literature has consistently supported that there are significant differences in mitral regurgitation outcomes between male and female patients and that this is likely multifactorial. Numerous sex differences in anatomy and pathophysiology may play a role in delayed diagnoses, referrals, and treatments for female patients. Despite the recognition of these discrepancies in the literature, many guidelines that steer clinical care do not incorporate these factors into society recommendations. Identifying and validating sex-specific diagnostic parameters and increasing the representation of female patients in trials of new mitral regurgitation treatment modalities are key factors in improving outcomes for female patients.
二尖瓣反流是最常见的瓣膜疾病，在老年人中尤为如此。最近的文献一致支持，男性和女性患者在二尖瓣反流的治疗结果上存在显著差异，而且这可能是多因素导致的。解剖学和病理生理学方面的众多性别差异可能在女性患者的诊断延迟、转诊和治疗中起作用。尽管文献中已经认识到这些差异，但许多指导临床护理的指南并未将这些因素纳入社会建议中。识别和验证性别特异性诊断参数以及增加女性患者在新的二尖瓣反流治疗方式试验中的代表性是改善女性患者治疗结果的关键因素。
